Nanotechnology strategies for endometrium health: Are we on the right track?
Source abstract
Abstract
The endometrium is a vital mucosal tissue which undergoes cyclical regeneration, differentiation, and remodeling upon hormonal, cellular, and molecular signaling networks. Dysregulation of these processes can trigger a range of pathological conditions including chronic inflammatory disorders, hyperplastic lesions, malignancies, and infertility, necessitating the need for effective therapeutic interventions. Furthermore, we are still dependent on conventional treatment modalities which are often constrained by inefficient drug biodistribution, systemic toxicity, and emergence of therapeutic resistance. Recently, nanomedicines have gained tremendous attention in human healthcare, because they not only diagnose the disease but also deliver therapeutic agents to the targeted site without affecting healthy organs. There are numerous nanotechnology-based approaches that have been applied for clinical usage(s). In addition, recent advances in nanoparticle-based photothermal therapy, immunomodulatory approaches, and molecular imaging techniques have demonstrated considerable potential in refining both therapeutic and diagnostic strategies for endometrial pathologies. Herein, we reviewed a comprehensive analysis of nanotechnology-driven innovations in endometrial disease management, elucidating their mechanistic foundations, translational prospects, and future trajectories in endometrium and gynecological nanomedicine.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Endometriosis Research and Treatment · Reproductive System and Pregnancy · Pregnancy and Medication Impact
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Hormonal pathology of the endometrium10.1038/modpathol.3880050 ↗
2. Physiology of the endometrium and regulation of menstruation
3. Through thick and thin: a pictorial review of the endometrium10.1007/s00261-016-0930-5 ↗
4. Targeted nanoparticles for imaging and therapy of endometriosis10.1093/biolre/ioae073 ↗
5. Therapeutic potential of nanotechnology in reproduction disorders and possible limitations10.1017/S0967199423000424 ↗
6. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine10.2174/0929867328666210705144456 ↗
7. Rethinking the application of nanoparticles in women's reproductive health and assisted reproduction10.2217/nnm-2023-0346 ↗
8. The role of nanomedicine in benign gynecologic disorders10.3390/molecules29092095 ↗
9. The application of nanoparticle-based imaging and phototherapy for female reproductive organs diseases
10. Recent advances in nanotechnology-based drug delivery systems for the diagnosis and treatment of reproductive disorders10.1021/acsabm.3c01064 ↗
11. In situ photo responsive biodegradable nanoparticle forming intrauterine implant for drug delivery to treat ovarian diseases: a rationale-based review
12. Nanoparticles in pregnancy: the next frontier in reproductive therapeutics10.1093/humupd/dmaa049 ↗
13. [drug discovery by formulation design and innovative drug delivery systems (DDS)]10.1248/yakushi.131.1271 ↗
14. A comprehensive review of advanced diagnostic techniques for endometriosis: new approaches to improving women's well-being
15. Nanomedicines for endometriosis: lessons learned from cancer research10.1002/smll.202004975 ↗
16. Drug delivery for the treatment of endometriosis and uterine fibroids10.1007/s13346-017-0423-2 ↗
17. Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers10.1186/s12943-024-02163-z ↗
18. Placenta-targeted treatment strategies for preeclampsia and fetal growth restriction: an opportunity and major challenge10.1007/s12015-024-10739-x ↗
19. Particles and prejudice: Nanomedicine approaches to reducing health disparities in endometrial cancer
20. Benefit of silver and gold nanoparticles in wound healing process after endometrial cancer protocol10.3390/biomedicines10030679 ↗
21. Sentinel lymph node mapping in endometrial cancer after 2020 ESGO-ESTRO-ESP consensus update: what will happen in the next few years?
22. Comparison of different tracers in sentinel lymph node detection for endometrial cancer: a systematic review and network meta-analysis10.1097/JS9.0000000000002064 ↗
23. Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas
24. Voices of nanomedicine: blueprint guidelines for collaboration in addressing global unmet medical needs10.1021/acsnano.4c13513 ↗
25. Different effects of the immunomodulatory drug GMDP immobilized onto aminopropyl modified and unmodified mesoporous silica nanoparticles upon peritoneal macrophages of women with endometriosis10.1155/2013/924362 ↗
26. Mitigation of endometriosis using regenerative cerium oxide nanoparticles10.1016/j.nano.2012.08.001 ↗
27. Nanoceria as a non-steroidal anti-inflammatory drug for endometriosis theranostics10.1016/j.jconrel.2024.12.074 ↗
28. Nanoparticle-assisted combinatorial therapy for effective treatment of endometriosis10.1166/jbn.2015.2020 ↗
29. Development and characterization of poly(lactic-co-glycolic) acid nanoparticles loaded with copaiba oleoresin10.1080/10837450.2017.1290107 ↗
30. Effect of PLGA nanoparticle-mediated delivery of miRNA 503 on the apoptosis of ovarian endometriosis cells
31. Microfluidics-derived hierarchical microparticles for the delivery of dienogest for localized endometriosis therapy10.1016/j.actbio.2024.02.017 ↗
32. Preparation of letrozole dispersed pHEMA/AAm-g-LDPE drug release system: in-Vitro release kinetics for the treatment of endometriosis10.1016/j.colsurfb.2019.04.014 ↗
33. miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo10.1186/s13287-017-0706-z ↗
34. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells10.1182/blood.V52.6.1099.1099 ↗
35. mRNA levels of low-density lipoprotein receptors are overexpressed in the foci of deep bowel endometriosis10.1093/humrep/dew303 ↗
36. Nanotechnology for the treatment of deep endometriosis: uptake of lipid core nanoparticles by LDL receptors in endometriotic foci10.6061/clinics/2019/e989 ↗
37. Pilot study of treatment of patients with deep infiltrative endometriosis with methotrexate carried in lipid nanoparticles10.1007/s00404-023-07246-8 ↗
38. β-Caryophyllene causes regression of endometrial implants in a rat model of endometriosis without affecting fertility10.1016/j.ejphar.2013.01.011 ↗
39. Development, characterization and evidence of anti-endometriotic activity of phytocannabinoid-rich nanoemulsions10.1016/j.ijpharm.2023.123049 ↗
40. Gene therapy of endometriosis introduced by polymeric micelles with glycolipid-like structure10.1016/j.biomaterials.2011.09.077 ↗
41. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain10.2147/IJN.S146569 ↗
42. Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway
43. Lipoxin A4 suppresses IL-1β-Induced Cyclooxygenase-2 expression through inhibition of p38 MAPk activation in endometriosis10.1177/1933719119828115 ↗
44. BML-111 attenuates high glucose-induced inflammation, oxidative stress and reduces extracellular matrix accumulation via targeting Nrf2 in rat glomerular mesangial cells10.1016/j.intimp.2019.106108 ↗
45. A multifunctional nanoparticle for efferocytosis and pro-resolving-mediated endometriosis therapy10.1016/j.colsurfb.2022.112893 ↗
46. Cell-penetrating peptide and siRNA-Mediated therapeutic effects on endometriosis and cancer in vitro models10.3390/pharmaceutics13101618 ↗
47. Nanoparticle-based platform for activatable fluorescence imaging and photothermal ablation of endometriosis
48. Targeted nanoparticles with high heating efficiency for the treatment of endometriosis with systemically delivered magnetic hyperthermia
49. Injectable hydrogel nanoarchitectonics with near-infrared controlled drug delivery for in situ photothermal/endocrine synergistic endometriosis therapy10.1186/s40824-023-00442-2 ↗
50. Injectable Magnetic Hydrogel Incorporated with Anti-Inflammatory Peptide for Efficient Magnetothermal Treatment of Endometriosis10.1002/advs.202409778 ↗
51. Peritoneal immune microenvironment of endometriosis: role and therapeutic perspectives
52. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model10.1016/j.ejps.2016.10.031 ↗
53. [experimental research on the treatment of mouse endometriosis model with nanoparticles loaded with CCR5-antibody]
54. Targeting delivery of mifepristone to endometrial dysfunctional macrophages for endometriosis therapy10.1016/j.actbio.2024.09.037 ↗
55. iRGD-Targeted peptide nanoparticles for anti-angiogenic RNAi-Based therapy of endometriosis10.3390/pharmaceutics15082108 ↗
56. Hyaluronic acid-modified nanoplatforms as a vector for targeted delivery of autophagy-related gene to the endometriotic lesions in mice
57. Homing peptide-based targeting of Tenascin-C and fibronectin in endometriosis10.3390/nano11123257 ↗
58. Neutrophil recruitment and function in endometriosis patients and a syngeneic murine model10.1096/fj.201902272R ↗
59. Increased levels of human neutrophil peptides 1, 2, and 3 in peritoneal fluid of patients with endometriosis: association with neutrophils, T cells and IL-810.1016/j.jri.2011.05.008 ↗
60. Highly specific neutrophil-mediated delivery of albumin nanoparticles to ectopic lesion for endometriosis therapy10.1186/s12951-023-01831-4 ↗
61. Endometriosis-targeted MRI imaging using bevacizumab-modified nanoparticles aimed at vascular endothelial growth factor10.1039/D2NA00787H ↗
62. Imaging of endometriotic lesions using cRGD-MN probe in a mouse model of endometriosis10.3390/nano14030319 ↗
63. Photoacoustic imaging endometriosis lesions with nanoparticulate polydopamine as a contrast agent10.1002/adhm.202302175 ↗
64. A mouse model of endometriosis with nanoparticle labeling for in vivo photoacoustic imaging10.1007/s43032-022-00980-5 ↗
65. A nanoparticle-lectin immunoassay improves discrimination of serum CA125 from malignant and benign sources10.1373/clinchem.2016.257691 ↗
66. Europium nanoparticle-based Sialyl-Tn monoclonal antibody discriminates epithelial ovarian cancer-associated CA125 from benign sources10.1373/jalm.2018.028266 ↗
67. Label-free electrochemical immunosensor based on one-step electrochemical deposition of AuNP-RGO nanocomposites for detection of endometriosis marker CA 12510.1021/acsabm.0c00821 ↗
68. Biogenesis of copper nanoparticles (Cu-NPs) using leaf extract of Allium noeanum, antioxidant and in-vitro cytotoxicity10.1080/21691401.2021.1926275 ↗
69. Exploring the potential of thymoquinone-stabilized selenium nanoparticles: in HEC1B endometrial cancer cells revealing enhanced anticancer efficacy10.1021/acsomega.3c06028 ↗
70. Enhancing of nanocatalyst-driven chemodynaminc therapy for endometrial cancer cells through inhibition of PINK1/Parkin-Mediated mitophagy10.2147/IJN.S329341 ↗
71. Combination of disulfiram and copper-cysteamine nanoparticles induces mitochondria damage and promotes apoptosis in endometrial cancer
72. Superparamagnetic iron oxide nanoparticle-mediated expression of miR-326 inhibits human endometrial carcinoma stem cell growth10.2147/IJN.S200480 ↗
73. Synthetically lethal nanoparticles for treatment of endometrial cancer10.1038/s41565-017-0009-7 ↗
74. MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy10.1016/j.ygyno.2019.08.014 ↗
75. Fabrication of polymer-based self-assembly nanocarriers loaded with a crizotinib and gemcitabine: potential therapeutics for the treatment of endometrial cancer10.1080/09205063.2021.1974149 ↗
76. Ciprofloxacin derivative-loaded nanoparticles synergize with paclitaxel against type II human endometrial cancer
77. The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-Coated PLGA-PEG nanoparticles10.1007/s13346-021-01065-7 ↗
78. Targeting cancer metabolism plasticity with JX06 nanoparticles via inhibiting PDK1 combined with metformin for endometrial cancer patients with diabetes10.1002/advs.202104472 ↗
79. Clinical and biological significance of EZH2 expression in endometrial cancer10.1080/15384047.2019.1672455 ↗
80. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement10.1158/2159-8290.CD-12-0429 ↗
81. Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-α (ER-α) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female sprague-dawley rats10.1016/j.ijbiomac.2016.12.055 ↗
82. Mononuclear phagocyte system function and nanoparticle pharmacology in Obese and normal weight ovarian and endometrial cancer patients10.1007/s00280-018-3702-9 ↗
83. Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers10.1111/cas.14907 ↗
84. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal
85. Carboplatin-loaded ultradeformable vesicles for the management of endometrial cancer: in vitro and in vivo evaluation10.4155/tde-2022-0039 ↗
86. Fabrication of controlled-release polymeric microneedles containing progesterone-loaded self-microemulsions for transdermal delivery10.1080/10837450.2024.2307996 ↗
87. Inhibitory effects of brusatol delivered using glycosaminoglycan-placental chondroitin sulfate A-modified nanoparticles on the proliferation, migration and invasion of cancer cells10.3892/ijmm.2020.4627 ↗
88. Aptamer-functionalized gold nanoparticles for drug delivery to gynecological carcinoma cells10.3390/cancers13164038 ↗
89. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma10.1016/j.bmc.2011.05.016 ↗
90. Hyaluronic acid-functionalized nanomicelles enhance SAHA efficacy in 3D endometrial cancer models10.3390/cancers13164032 ↗
91. Novel endometrial cancer models using sensitive metastasis tracing for CXCR4-Targeted therapy in advanced disease10.3390/biomedicines10071680 ↗
92. Potent anticancer activity of CXCR4-Targeted nanostructured toxins in aggressive endometrial cancer models10.3390/cancers15010085 ↗
93. Dual-multivalent aptamer-based drug delivery platform for targeted SRC silencing to enhance doxorubicin sensitivity in endometrial cancer10.7150/ijbs.101059 ↗
94. Comparison study of laparoscopic sentinel lymph node mapping in endometrial carcinoma using carbon nanoparticles and lymphatic pathway verification10.1016/j.jmig.2018.11.002 ↗
95. Carbon nanoparticles combined with indocyanine green for sentinel lymph node detection in endometrial carcinoma10.1002/jso.26518 ↗
96. Comparing carbon nanoparticles and indocyanine green for sentinel lymph node mapping in endometrial cancer: a randomized-controlled single-center trial10.1002/jso.27268 ↗
97. Sentinel lymph node biopsy with carbon dye in endometrial cancer: a single center, prospective cohort study10.1007/s00464-023-10662-1 ↗
98. [clinical analysis of 76 cases of sentinel lymph node detection in cervical cancer and endometrial cancer
99. Comparison of sentinel lymph node distribution and lymphatic drainage pathway between high- and low-risk endometrial cancers10.1007/s00404-023-07111-8 ↗
100. Coordination of nanoconjugation with an antigen/antibody for efficient detection of gynecological tumors10.1155/2020/6528572 ↗